---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-010039"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:35:34.902977+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix secures GPO coverage for TONMYA, expanding commercial access to ~35M patients

## Summary
- Agreement effective May 1, 2026 with leading GPO provides coverage for ~35M U.S. commercial lives (20% of ~177M total).
- TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years; commercially launched November 2025.
- TONMYA now covered under Medicaid in 38 states, representing ~55M beneficiaries (73% of ~75M Medicaid lives).
- Coverage includes standard utilization management criteria; patient savings program available for eligible commercially insured.
- CEO Seth Lederman emphasizes continued pursuit of additional commercial and government channel coverage.

## SEC filing metadata
- accession: 0001999371-26-010039
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010039/0001999371-26-010039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010039/tnxp_8k-050626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-010039
- JSON: https://secwatch.observer/filing/0001999371-26-010039.json
- Plain text: https://secwatch.observer/filing/0001999371-26-010039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.